you are here: Home News Business

Business

IPO-bound cardiac stent maker Integris Medtech turns profitable in FY25, approaches capital markets for debt reduction
Everstone-backed Integris Medtech files for Rs 3,500-4,000 crore IPO
How tainted cough syrups slip through India’s broken drug oversight
TCS Q2 show in-line, while Street 'unclear' on data centre push; should you buy, sell, or hold?
Midwest trims IPO size to Rs 451 crore; issue opens for subscription on October 15
No compromise of TCS systems in recent cyberattacks on clients, says COO
Canara HSBC Life Insurance raises over Rs 750 crore via anchor book of Rs 2,517-crore IPO
Alpha Alternatives Fund Advisors-sponsored Anantam Highways Trust IPO subscribed 5.62 times on final day
TCS to invest $6-7 billion into building data centers; first revenues 18–24 months after start
Indian patients demand transparency, willing to pay more for certified quality says FICCI & EY-Parthenon report
Roche faces setback as Delhi high court clears Natco Pharma's low cost generic Risdiplam
Saya Group, Harmony Infra to develop Rs 1,600-crore ultra-luxury project in Indirapuram
Mittal Sections IPO closes with 2.19 times subscription; check its listing, allotment dates
TCS to launch a new entity to establish multiple AI and Sovereign Data Centers in India
TCS posts broad-based growth in Q2, order book grows 16.2% YoY to $10 billion
Can Q2 FY26 earnings bring back FIIs to Indian markets?
Rubicon Research raises Rs 619 crore from 32 anchor investors ahead of Rs 1,377 crore IPO
Canara Robeco AMC mobilises Rs 398 crore via anchor book, Rs 1,326 crore IPO to open for public on October 9
Health adtech player Indegene rides Trump pharma shakeup with AI-driven outreach
Weight-loss drug Mounjaro is India's second-highest selling pharma brand
Anantam Highways Trust IPO sees 41% subscription on day 1
Titan posts slower sales in Q2 as surge in gold prices dent demand
Structural steel products maker Mittal Sections IPO fully subscribed on day 1
USFDA to fast-track review of generics tested and made in US, but do Indian drugmakers need to worry?
WeWork India IPO sees 115% subscription on Day 3, led by QIB demand; check latest GMP

English

Markets

News

Personal Finance

Mutual Funds

Commodities

Media

Invest Now

Specials

Business

IPO-bound cardiac stent maker Integris Medtech turns profitable in FY25, approaches capital markets for debt reduction

Everstone-backed Integris Medtech files for Rs 3,500-4,000 crore IPO

How tainted cough syrups slip through India’s broken drug oversight

TCS Q2 show in-line, while Street 'unclear' on data centre push; should you buy, sell, or hold?

Midwest trims IPO size to Rs 451 crore; issue opens for subscription on October 15

No compromise of TCS systems in recent cyberattacks on clients, says COO

Canara HSBC Life Insurance raises over Rs 750 crore via anchor book of Rs 2,517-crore IPO

Alpha Alternatives Fund Advisors-sponsored Anantam Highways Trust IPO subscribed 5.62 times on final day

TCS to invest $6-7 billion into building data centers; first revenues 18–24 months after start

Indian patients demand transparency, willing to pay more for certified quality says FICCI & EY-Parthenon report

Roche faces setback as Delhi high court clears Natco Pharma's low cost generic Risdiplam

Saya Group, Harmony Infra to develop Rs 1,600-crore ultra-luxury project in Indirapuram

Mittal Sections IPO closes with 2.19 times subscription; check its listing, allotment dates

TCS to launch a new entity to establish multiple AI and Sovereign Data Centers in India

TCS posts broad-based growth in Q2, order book grows 16.2% YoY to $10 billion

Can Q2 FY26 earnings bring back FIIs to Indian markets?

Rubicon Research raises Rs 619 crore from 32 anchor investors ahead of Rs 1,377 crore IPO

Canara Robeco AMC mobilises Rs 398 crore via anchor book, Rs 1,326 crore IPO to open for public on October 9

Health adtech player Indegene rides Trump pharma shakeup with AI-driven outreach

Weight-loss drug Mounjaro is India's second-highest selling pharma brand

Anantam Highways Trust IPO sees 41% subscription on day 1

Titan posts slower sales in Q2 as surge in gold prices dent demand

Structural steel products maker Mittal Sections IPO fully subscribed on day 1

USFDA to fast-track review of generics tested and made in US, but do Indian drugmakers need to worry?

WeWork India IPO sees 115% subscription on Day 3, led by QIB demand; check latest GMP